Canada
· Delayed Price · Currency is CAD Medexus Pharmaceuticals Statistics
Total Valuation
Medexus Pharmaceuticals has a market cap or net worth of CAD 80.12 million. The enterprise value is 128.76 million.
| Market Cap | 80.12M |
| Enterprise Value | 128.76M |
Important Dates
The next estimated earnings date is Thursday, February 6, 2025.
| Earnings Date | Feb 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Medexus Pharmaceuticals has 24.65 million shares outstanding. The number of shares has increased by 18.66% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 24.65M |
| Shares Change (YoY) | +18.66% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 9.64% |
| Owned by Institutions (%) | 8.06% |
| Float | 22.27M |
Valuation Ratios
The trailing PE ratio is 27.60 and the forward PE ratio is 7.69.
| PE Ratio | 27.60 |
| Forward PE | 7.69 |
| PS Ratio | 0.56 |
| PB Ratio | 1.81 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 2.68 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.12, with an EV/FCF ratio of 4.31.
| EV / Earnings | 41.53 |
| EV / Sales | 0.91 |
| EV / EBITDA | 5.12 |
| EV / EBIT | 7.43 |
| EV / FCF | 4.31 |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 1.31.
| Current Ratio | 1.01 |
| Quick Ratio | 0.32 |
| Debt / Equity | 1.31 |
| Debt / EBITDA | 2.31 |
| Debt / FCF | 1.94 |
| Interest Coverage | 1.41 |
Financial Efficiency
Return on equity (ROE) is 8.42% and return on invested capital (ROIC) is 9.45%.
| Return on Equity (ROE) | 8.42% |
| Return on Assets (ROA) | 5.14% |
| Return on Capital (ROIC) | 9.45% |
| Revenue Per Employee | 1.73M |
| Profits Per Employee | 37,810 |
| Employee Count | 82 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 1.40 |
Taxes
In the past 12 months, Medexus Pharmaceuticals has paid 439,880 in taxes.
| Income Tax | 439,880 |
| Effective Tax Rate | 301.89% |
Stock Price Statistics
The stock price has increased by +48.40% in the last 52 weeks. The beta is 1.96, so Medexus Pharmaceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 1.96 |
| 52-Week Price Change | +48.40% |
| 50-Day Moving Average | 2.57 |
| 200-Day Moving Average | 2.17 |
| Relative Strength Index (RSI) | 67.32 |
| Average Volume (20 Days) | 25,425 |
Short Selling Information
The latest short interest is 136,766, so 0.56% of the outstanding shares have been sold short.
| Short Interest | 136,766 |
| Short Previous Month | 128,926 |
| Short % of Shares Out | 0.56% |
| Short % of Float | 0.62% |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medexus Pharmaceuticals had revenue of CAD 141.52 million and earned 3.10 million in profits. Earnings per share was 0.12.
| Revenue | 141.52M |
| Gross Profit | 81.87M |
| Operating Income | 17.32M |
| Pretax Income | 2.05M |
| Net Income | 3.10M |
| EBITDA | 24.96M |
| EBIT | 17.32M |
| Earnings Per Share (EPS) | 0.12 |
Balance Sheet
The company has 9.42 million in cash and 58.06 million in debt, giving a net cash position of -48.64 million or -1.97 per share.
| Cash & Cash Equivalents | 9.42M |
| Total Debt | 58.06M |
| Net Cash | -48.64M |
| Net Cash Per Share | -1.97 |
| Equity (Book Value) | 44.23M |
| Book Value Per Share | 1.79 |
| Working Capital | 1.01M |
Cash Flow
In the last 12 months, operating cash flow was 29.99 million and capital expenditures -101,321, giving a free cash flow of 29.88 million.
| Operating Cash Flow | 29.99M |
| Capital Expenditures | -101,321 |
| Free Cash Flow | 29.88M |
| FCF Per Share | 1.21 |
Margins
Gross margin is 57.85%, with operating and profit margins of 12.24% and 2.19%.
| Gross Margin | 57.85% |
| Operating Margin | 12.24% |
| Pretax Margin | 1.45% |
| Profit Margin | 2.19% |
| EBITDA Margin | 17.64% |
| EBIT Margin | 12.24% |
| FCF Margin | 21.12% |
Dividends & Yields
Medexus Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.66% |
| Shareholder Yield | -18.66% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
The last stock split was on December 19, 2018. It was a reverse split with a ratio of 0.0666666.
| Last Split Date | Dec 19, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.0666666 |
Scores
Medexus Pharmaceuticals has an Altman Z-Score of 0.61 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.61 |
| Piotroski F-Score | 2 |